Company Description: CytoArm focuses on untreatable diseases through a next generation T cell therapy, Armed-T cell. We are led by experts in both business & medical area, with comprehensive experience in the development of novel T-cell therapies for clinical treatments. Our core technology, a cutting-edge virus-free T cell manufacturing platform, offers a single-step manufacturing process to obtain high purity (>90%) cancer-specific T cells in only one third of the time compared to current CAR-T cell therapy. The first Armed-T cell product, targeting the treatment of colorectal cancer with EGFR downstream gene mutations, is ready to initiate an clinical trial in 2024.